project id: TCGA-PAAD; case submitter id: TCGA-3A-A9IJ; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.9; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.71; rna integrity number: 8.7; age at index: 65; days to birth: -23791; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1944; age at diagnosis: 23791; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic stage: Stage IB; ajcc pathologic t: T2; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1854.0; icd 10 code: C25.0; last known disease status: not reported; morphology: 8246/3; primary diagnosis: Neuroendocrine carcinoma, NOS; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Head of pancreas; synchronous malignancy: No; tissue or organ of origin: Head of pancreas; tumor grade: Not Reported; year of diagnosis: 2009; treatment or therapy: no; alcohol history: No; cigarettes per day: 1.36986301369863; pack years smoked: 25.0; years smoked: 30.0; is ffpe: false; weight: 30.0; composition: Not Reported; days to collection: 1520; days to sample procurement: 0; initial weight: 50.0; portion submitter id: TCGA-3A-A9IJ-01A-11; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 10.0; percent tumor cells: 90.0; percent tumor nuclei: 90.0;